ISTA Pharmaceuticals, Inc.
Irvine, California, 92618, United States
NCT Number: NCT01212471
A dose ranging study to evaluate safety and efficacy of bromfenac ophthalmic solution in dry eye disease.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Irvine, California, 92618, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
sterile ophthalmic solution
sterile ophthalmic solution
sterile ophthalmic solution
Time frame: 42 days
The Ocular Surface Disease Index (OSDI) is a 12 item questionnaire. Each question about discomfort/limitations is scored from 0 to 4, with 0 being 'None of the Time' and 4 being 'All of the Time'. The minimum total score is 0 and the maximum total score is 48, with higher scores indicating worse outcomes.
Bausch & Lomb Incorporated
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04343287
Dry Eye Syndrome, Dry Eye Syndromes
Newport Beach, California, United States
View Trial DetailsNCT03066219
Dry Eye Syndrome, Dry Eye Syndromes
Lewiston, Maine, United States
View Trial DetailsNCT06375499
Dry Eye Syndrome, Dry Eye Syndromes
Prague, Czechia
View Trial DetailsNCT01013077
Dry Eye Syndrome, Dry Eye Syndromes
Fullerton, California, United States
View Trial Details